Octapharma Announces $1.5 Billion Biomedical Manufacturing Facility in Rock Hill, SC

Octapharma's New $1.5 Billion Manufacturing Facility in Rock Hill, SC

In a major announcement on July 29, 2026, Octapharma, the world's largest privately owned plasma fractionator, revealed its plans to build an advanced manufacturing facility at the Palmetto Research Park in Rock Hill, South Carolina. With an investment of $1.5 billion, this state-of-the-art plant is poised to become a pivotal asset in the biomedical landscape of the United States, generating around 1,500 full-time job opportunities.

A Significant Investment in South Carolina

The new facility is set to be one of the largest private biomedical investments in the state’s history. By establishing this manufacturing site, Octapharma aims to bolster domestic production capabilities for its range of plasma-based therapies. This strategic move is expected to enhance the resilience of America's biomedical supply chain, which has increasingly relied on imports.

CEO and Chairman Wolfgang Marguerre shared insights on the necessity of this expansion, stating, "We expect significant future growth driven by our existing life-saving therapies and a strong pipeline of new products. Our manufacturing capacity must evolve to support this ambition, and our US manufacturing facility will be an important milestone." He emphasized the national security importance of local production for critical healthcare resources, saying, "Having the ability to produce and supply our therapies domestically is invaluable."

Meeting Local Health Needs

The Rock Hill site will focus on producing several life-saving medicines and vital trauma care products tailored for national security and emergency preparedness. This move aligns with a growing demand for domestic health solutions, particularly in light of recent global supply chain disruptions. The location was thoughtfully selected based on its existing infrastructure, which supports advanced manufacturing practices, accessibility to deep-water ports, and close proximity to key logistics networks.

Tobias Marguerre, Deputy Chairman of Octapharma, noted, "As the demand in the US for our portfolio of products continues to grow, the new US manufacturing site will bring production closer to both the plasma donated in the US and to the patients who rely on them."

Community Commitment and Economic Growth

The establishment of the new facility reinforces Octapharma's commitment to not just biomedical innovation but also to the local community. The company has pledged to collaborate closely with Rock Hill and York County officials and other stakeholders to ensure that the benefits of this significant investment are felt throughout the region.

"We appreciate the good-faith work of every elected official and staff member in York County and Rock Hill who helped bring this to fruition," remarked Flemming Nielsen, President of Octapharma USA. Both local and state leaders have expressed their enthusiasm about the facility, which promises to be a boon for the South Carolina economy. Governor McMaster and the state delegation have been instrumental in supporting Octapharma's move to the Palmetto State.

Looking Forward

While a construction timeline and groundbreaking ceremony have yet to be announced, the local community eagerly awaits this economic catalyst. With South Carolina's strong educational pipeline, particularly in the life sciences and biomedical fields, Octapharma anticipates a stable workforce equipped to handle biopharmaceutical manufacturing at scale.

Octapharma, headquartered in Lachen, Switzerland, has been a leader in the development and production of therapies derived from human plasma and human cell lines, employing over 11,000 people and serving patients in 117 countries. The opening of this manufacturing site in South Carolina marks a significant step towards enhancing the company’s operational footprint in the US, ensuring that it can achieve its vision of delivering high-quality medical therapies more efficiently and reliably to those in need.

For more information about Octapharma and its innovative healthcare solutions, visit www.octapharma.com.